Respiratory Diseases

Your daily dose of the clinical news you may have missed.

RSV vaccines from Pfizer-BioNTech and Moderna for adults aged 60 years and older aren't that different, so which would you recommend if a patient asks?

The risk of severe CV events, including leading to death, was greatest in the first week following an exacerbation but remained significantly elevated 1 year later.

Your daily dose of the clinical news you may have missed.

After hospital discharge, persons who had COVID-19 remained at greater risk of death and myriad adverse health outcomes compared with those who had seasonal flu.

Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.

Higher serum levels of the omega-3 fatty acids were associated with slowed disease progression and longer transplant-free survival in a new study.

If approved the 21-valent shot would be the first pneumococcal conjugate vaccine indicated specifically for adults.

Your daily dose of the clinical news you may have missed.

The coadministration of RSVpreF and seasonal influenza vaccine was found to generate robust immune responses in older adults, reported authors of new study.

The finding implies the potential for virus transmission after initial recovery from the infection, according to study authors.

According to the US CDC, the most important modifiable risk factor for antibiotic resistance is (fill in this blank). Find out here and fill in 5 more blanks.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

A new meta-analysis found prevalence of asthma higher in countries with better air quality, higher income status, and health care access.

Infants who attended a recommended follow-up clinic visit after being seen in an ED were also slightly more likely to receive medications outside of guideline recommendations.

Data presented at CHEST 2023 shows treatment with hydrocortisone is associated with a decrease in morality among patients with community-acquired pneumonia.

Your daily dose of the clinical news you may have missed.

First nonprescription daily oral contraceptive pill, OTC opioid antagonist nasal spray for opioid overdose, and 5 more FDA-approved drugs primary care clinicians should know about.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.

IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,

A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.

Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.

The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.

The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.

COVID-19, influenza, and RSV will be the topics of a different types of sessions examining the history, new diagnostics, prevention, and future treatments during IDWeek 2023.

Many patients with moderate-to-severe asthma may not be using inhaled corticosteroids along with rescue medications to avoid serious disease exacerbations.

Influenza B is the diagnosis and the patient wants to start antiviral therapy. Factoring in CDC guidance, patient preference, and price, which of the 4 options makes most sense?